Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT07023341 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT07023341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07023341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 30, 2025
Completion date
April 28, 2028
Enrollment
36 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive hypertrophic cardiomyopathy